Pharmacological Characterization of the αvβ6 Integrin Binding and Internalization Kinetics of the Foot-and-Mouth Disease Virus Derived Peptide A20FMDV2

Pharmacology

Volumn 97, Issue 3-4, 2016, Pages 114-125

  Slack, Robert J ^a   Hafeji, Maryam ^a   Rogers, Rebecca ^a   Ludbrook, Steve B ^b   Marshall, John F ^c   Flint, David J ^d   Pyne, Susan ^d   Denyer, Jane C ^a  

^a Respiratory TAU   (United Kingdom)

^b Platform Technology and Science   (United Kingdom)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

A20FMDV2; Binding kinetics; Internalization kinetics; Latency associated peptide 1; v 6 integrin

Indexed keywords

ALPHAVBETA6 INTEGRIN; LATENCY ASSOCIATED PEPTIDE; LATENCY ASSOCIATED PEPTIDE 1; PEPTIDE A20FMDV2; PEPTIDE DERIVATIVE; RADIOLIGAND; UNCLASSIFIED DRUG; VIRUS PROTEIN; INTEGRIN; LIGAND; PEPTIDE; PROTEIN BINDING; TUMOR ANTIGEN;

ARTICLE; BINDING AFFINITY; BINDING SITE; BRONCHUS; CELL SURFACE; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG PROTEIN BINDING; DRUG SELECTIVITY; EPITHELIUM CELL; FLOW CYTOMETRY; FOOT AND MOUTH DISEASE VIRUS; HUMAN; HUMAN CELL; INTERNALIZATION; ISOTOPE LABELING; NORMAL HUMAN; PRIORITY JOURNAL; CELL LINE; KINETICS; METABOLISM; RADIOASSAY;

ANTIGENS, NEOPLASM; BINDING SITES; CELL LINE; FOOT-AND-MOUTH DISEASE VIRUS; HUMANS; INTEGRINS; KINETICS; LIGANDS; PEPTIDES; PROTEIN BINDING; RADIOLIGAND ASSAY;

EID: 84953792223     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000443180     Document Type: Article

References (37)

1. Hynes RO: Integrins: a family of cell surface receptors. Cell 1997; 48: 549-554.
2. Hynes RO: Integrins: bidirectional, allosteric signaling machines. Cell 2002; 110: 673-687.
3. Faull RJ, Ginsberg MH: Inside-out signaling through integrins. J Am Soc Nephrol 1996; 7: 1091-1097.
4. Ruoslahti E: RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol 1996; 12: 697-715.
5. Busk M, Pytela R, Sheppard D: Characterization of the integrin alpha v beta 6 as a fibronectin-binding protein. J Biol Chem 1992; 267: 5790-5796.
6. Huang XZ, Wu JF, Cass D, Erle DJ, Corry D, Young SG, et al: Inactivation of the integrin beta 6 subunit gene reveals a role of epithelial integrins in regulating inflammation in the lungs and skin. J Cell Biol 1996; 133: 921-928.
7. Munger JS, Huang X, Kawakatsu H, Griffiths MJ, Dalton SL, Wu J, et al: The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 1999; 96: 319-328.
8. Breuss JM, Gallo J, DeLisser HM, Klimanskaya IV, Folkesson HG, Pittet JF, et al: Expression of the beta 6 integrin subunit in development, neoplasia and tissue repair suggests a role in epithelial remodeling. J Cell Sci 1995; 108(pt 6):2241-2251.
9. Horan GS, Wood S, Ona V, Li DJ, Lukashev ME, Weinreb PH, et al: Partial inhibition of integrin alpha(v)beta6 prevents pulmonary fibrosis without exacerbating inflammation. Am J Respir Crit Care Med 2008; 177: 56-65.
10. Popov Y, Patsenker E, Stickel F, Zaks J, Bhaskar KR, Niedobitek G, et al: Integrin alphavbeta6 is a marker of the progression of biliary and portal liver fibrosis and a novel target for antifibrotic therapies. J Hepatol 2008; 48: 453-464.
11. Sheppard D: Roles of alphav integrins in vascular biology and pulmonary pathology. Curr Opin Cell Biol 2004; 16: 552-557.
12. Bandyopadhyay A, Raghavan S: Defining the role of integrin alphavbeta6 in cancer. Curr Drug Targets 2009; 10: 654-652.
13. Eberlein C, Kendrew J, McDaid K, Alfred A, Kang JS, Jacobs VN, Ross SJ, et al: A human monoclonal antibody 264RAD targeting ?v?6 integrin reduces tumour growth and metastasis, and modulates key biomarkers in vivo. Oncogene 2012; 32: 4406-4416.
14. Hausner SH, DiCara D, Marik J, Marshall JF, Sutcliffe JL: Use of a peptide derived from foot-and-mouth disease virus for the noninvasive imaging of human cancer: generation and evaluation of 4-[ 18 F]Fluorobenzoyl A20FMDV2 for in vivo imaging of alphavbeta6 integrin expression with positron emission tomography. Cancer Res 2007; 67: 7833-7840.
15. Hausner SH, Abbey CK, Bold RJ, Gagnon MK, Marik J, Marshall JF, et al: Targeted in vivo imaging of integrin alphavbeta6 with an improved radiotracer and its relevance in a pancreatic tumor model. Cancer Res 2009; 69: 5843-5850.
16. Saha A, Ellison D, Thomas GJ, Vallath S, Mather SJ, Hart IR, et al: High-resolution in vivo imaging of breast cancer by targeting the pro-invasive integrin alphavbeta6. J Pathol 2010; 222: 52-63.
17. John AE, Luckett JC, Tatler AL, Awais RO, Desai A, Habgood A, et al: Preclinical SPECT/CT imaging of ?v?6 integrins for molecular stratification of idiopathic pulmonary fibrosis. J Nucl Med 2013; 54: 2146-2147.
18. Carron CP, Meyer DM, Pegg JA, Engleman VW, Nickols MA, Settle SL, et al: A peptidomimetic antagonist of the integrin alpha(v) beta3 inhibits leydig cell tumor growth and the development of hypercalcemia of malignancy. Cancer Res 1998; 58: 1930-1935.
19. Goodman SL, Hölzemann G, Sulyok GA, Kessler H: Nanomolar small molecule inhibitors for alphav(beta)6, alphav(beta)5, and alphav(beta)3 integrins. J Med Chem 2002; 45: 1045-1051.
20. Ivanov AI: Pharmacological inhibition of endocytic pathways: is it specific enough to be useful? Methods Mol Biol 2008; 440: 15-33.
21. Motulsky H, Christopoulos A: Fitting Models to Biological Data using Linear and Nonlinear Regression: A Practical Guide to Curve Fitting, ed 1. New York, Oxford University Press, 2004.
22. Scatchard G: The attractions of proteins for small molecules and ions. Ann N Y Acad Sci 1949; 51: 660-672.
23. Hill AV: The mode of action of nicotine and curari, determined by the form of the contraction curve and the method of temperature coefficients. J Physiol 1909; 39: 361-373.
24. Cheng Y, Prusoff WH: Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 1973; 22: 3099-3108.
25. Dicara D, Burman A, Clark S, Berryman S, Howard MJ, Hart IR, et al: Foot-and-mouth disease virus forms a highly stable, EDTA-resistant complex with its principal receptor, integrin alphavbeta6: implications for infectiousness. J Virol 2008; 82: 1537-1546.
26. Mardon HJ, Grant KE: The role of the ninth and tenth type III domains of human fibronectin in cell adhesion. FEBS Lett 1994; 340: 197-201.
27. Kumar CC, Nie H, Rogers CP, Malkowski M, Maxwell E, Catino JJ, et al: Biochemical characterization of the binding of echistatin to integrin alphavbeta3 receptor. J Pharmacol Exp Ther 1997; 283: 843-853.
28. DiCara D, Rapisarda C, Sutcliffe JL, Violette SM, Weinreb PH, Hart IR, et al: Structurefunction analysis of Arg-Gly-Asp helix motifs in alpha v beta 6 integrin ligands. J Biol Chem 2007; 282: 9657-9665.
29. Lee JO, Bankston LA, Arnaout MA, Liddington RC: Two conformations of the integrin A-domain (I-domain): a pathway for activation? Structure 1995; 3: 1333-1340.
30. Plow EF, Haas TA, Zhang L, Loftus J, Smith JW: Ligand binding to integrins. J Biol Chem 2000; 275: 21785-21788.
31. Mariani M, Lang R, Binda E, Panina-Bordignon P, D'Ambrosio D: Dominance of CCL22 over CCL17 in induction of chemokine receptor CCR4 desensitization and internalization on human Th2 cells. Eur J Immunol 2004; 34: 231-240.
32. Sato T, Iwase M, Miyama M, Komai M, Ohshima E, Asai A, et al: Internalization of CCR4 and inhibition of chemotaxis by K777, a potent and selective CCR4 antagonist. Pharmacology 2013; 91: 305-313.
33. Weinreb PH, Simon KJ, Rayhorn P, Yang WJ, Leone DR, Dolinski BM: Function-blocking integrin alphavbeta6 monoclonal antibodies: distinct ligand-mimetic and nonligand-mimetic classes. J Biol Chem 2004; 279: 17875-17887.
34. Francis G, Kerem Z, Makkar HP, Becker K: The biological action of saponins in animal systems: a review. Br J Nutr 2002; 88: 587-605.
35. Ramsay AG, Keppler MD, Jazayeri M, Thomas GJ, Parsons M, Violette S, et al: HS1-associated protein X-1 regulates carcinoma cell migration and invasion via clathrin-mediated endocytosis of integrin alphavbeta6. Cancer Res 2007; 67: 5275-5284.
36. Wang J, Wu J, Hong J, Chen R, Xu K, Niu W, et al: PKC promotes the migration of colon cancer cells by regulating the internalization and recycling of integrin ?v?6. Cancer Lett 2011; 311: 38-47.
37. Dozynkiewicz MA, Jamieson NB, Macpherson I, Grindlay J, van den Berghe PV, von Thun A, et al: Rab25 and CLIC3 collaborate to promote integrin recycling from late endosomes/lysosomes and drive cancer progression. Dev Cell 2012; 22: 131-145.